Nektar Therapeutics dips after announcing equity offering

Shares of Nektar Therapeutics NKTR.O down 1.9% to $25.36 after potential equity raise news

San Francisco-based firm launches offering of stock and pre-funded warrants

It intends to use net proceeds for R&D, clinical development and manufacturing costs to support advancement of its drug candidates, along with other general purposes

Jefferies and Piper Sandler are jt bookrunners for offering

Last Tues, NKTR shares soared 156% to close at $24.45 after its eczema drug met main goal in mid-stage study

With ~12.4 mln shares outstanding, co has roughly $320 mln market cap

NKTR shares closed up 0.3% at $25.84 in Monday's regular session

Earlier this month, co effected 1-for-15 reverse stock split